Hostname: page-component-7c8c6479df-27gpq Total loading time: 0 Render date: 2024-03-28T02:35:58.842Z Has data issue: false hasContentIssue false

Cannabis use and first-episode psychosis: relationship with manic and psychotic symptoms, and with age at presentation

Published online by Cambridge University Press:  24 May 2013

J. M. Stone*
Affiliation:
Imperial College London, London, UK West London Mental Health NHS Trust, London, UK
H. L. Fisher
Affiliation:
Institute of Psychiatry, King's College London, London, UK
B. Major
Affiliation:
EQUIP, East London NHS Foundation Trust, London, UK
B. Chisholm
Affiliation:
Wandsworth Early Intervention Service, South West London and St George's Mental Health NHS Trust, London, UK
J. Woolley
Affiliation:
Wandsworth Early Intervention Service, South West London and St George's Mental Health NHS Trust, London, UK
J. Lawrence
Affiliation:
Southwark Early Intervention Service, South London and Maudsley NHS Foundation Trust, London, UK
N. Rahaman
Affiliation:
Westminster and Kensington & Chelsea Early Intervention Service, London, UK Central & North West London NHS Foundation Trust, London, UK
J. Joyce
Affiliation:
Lewisham Early Intervention Service, London, UK
M. Hinton
Affiliation:
University College London, London, UK Camden and Islington NHS Foundation Trust, London, UK
S. Johnson
Affiliation:
University College London, London, UK Camden and Islington NHS Foundation Trust, London, UK
A. H. Young
Affiliation:
Imperial College London, London, UK West London Mental Health NHS Trust, London, UK
*
*Address for correspondence: J. M. Stone, Ph.D., E517, Burlington Danes Building, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK. (Email: james.m.stone@imperial.ac.uk)

Abstract

Background

Cannabis use has been reported to be associated with an earlier onset of symptoms in patients with first-episode psychosis, and a worse outcome in those who continue to take cannabis. In general, studies have concentrated on symptoms of psychosis rather than mania. In this study, using a longitudinal design in a large naturalistic cohort of patients with first-episode psychosis, we investigated the relationship between cannabis use, age of presentation to services, daily functioning, and positive, negative and manic symptoms.

Method

Clinical data on 502 patients with first-episode psychosis were collected using the MiData audit database from seven London-based Early Intervention in psychosis teams. Individuals were assessed at two time points – at entry to the service and after 1 year. On each occasion, the Positive and Negative Syndrome Scale, Young Mania Rating Scale and Global Assessment of Functioning Scale disability subscale were rated. At both time points, the use of cannabis and other drugs of abuse in the 6 months preceding each assessment was recorded.

Results

Level of cannabis use was associated with a younger age at presentation, and manic symptoms and conceptual disorganization, but not with delusions, hallucinations, negative symptoms or daily functioning. Cannabis users who reduced or stopped their use following contact with services had the greatest improvement in symptoms at 1 year compared with continued users and non-users. Continued users remained more symptomatic than non-users at follow-up.

Conclusions

Effective interventions for reducing cannabis use may yield significant health benefits for patients with first-episode psychosis.

Type
Original Articles
Copyright
Copyright © Cambridge University Press 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Abel, KM, Drake, R, Goldstein, JM (2010). Sex differences in schizophrenia. International Review of Psychiatry 22, 417428.CrossRefGoogle ScholarPubMed
Andreasen, NC (1982). Negative symptoms in schizophrenia: definition and reliability. Archives of General Psychiatry 39, 784788.CrossRefGoogle ScholarPubMed
Barrowclough, C, Emsley, R, Eisner, E, Beardmore, R, Wykes, T (2013). Does change in cannabis use in established psychosis affect clinical outcome? Schizophrenia Bulletin 39, 339348.CrossRefGoogle ScholarPubMed
Drake, RE, Mueser, KT, McHugo, GJ (1996). Clinician rating scales: alcohol use scale (AUS), drug use scale (DUS), and substance abuse treatment scale (SATS). In Outcomes Assessment in Clinical Practice (ed. Sederer, L. I. and Dickey, B.), pp. 113116. Williams & Wilkins: Baltimore.Google Scholar
Endicott, J, Spitzer, RL, Fleiss, JL, Cohen, J (1976). The Global Assessment Scale. A procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry 33, 766771.CrossRefGoogle Scholar
Faber, G, Smid, HG, Van Gool, AR, Wunderink, L, van den Bosch, RJ, Wiersma, D (2012). Continued cannabis use and outcome in first-episode psychosis: data from a randomized, open-label, controlled trial. Journal of Clinical Psychiatry 73, 632638.CrossRefGoogle ScholarPubMed
Faridi, K, Joober, R, Malla, A (2012). Medication adherence mediates the impact of sustained cannabis use on symptom levels in first-episode psychosis. Schizophrenia Research 141, 7882.CrossRefGoogle ScholarPubMed
Fisher, H, Theodore, K, Power, P, Chisholm, B, Fuller, J, Marlowe, K, Aitchison, KJ, Tanna, R, Joyce, J, Sacks, M, Craig, T, Johnson, S (2008). Routine evaluation in first episode psychosis services: feasibility and results from the MiData project. Social Psychiatry and Psychiatric Epidemiology 43, 960967.CrossRefGoogle ScholarPubMed
Foti, DJ, Kotov, R, Guey, LT, Bromet, EJ (2010). Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. American Journal of Psychiatry 167, 987993.CrossRefGoogle ScholarPubMed
Ghali, S, Fisher, HL, Joyce, J, Major, B, Hobbs, L, Soni, S, Chisholm, B, Rahaman, N, Papada, P, Lawrence, J, Bloy, S, Marlowe, K, Aitchison, KJ, Power, P, Johnson, S (2012). Ethnic variations in pathways into early intervention services for psychosis. British Journal of Psychiatry. Published online 6 09 2012 . doi:bjp.bp.111.097865.Google ScholarPubMed
Gonzalez-Pinto, A, Alberich, S, Barbeito, S, Gutierrez, M, Vega, P, Ibanez, B, Haidar, MK, Vieta, E, Arango, C (2011). Cannabis and first-episode psychosis: different long-term outcomes depending on continued or discontinued use. Schizophrenia Bulletin 37, 631639.CrossRefGoogle ScholarPubMed
Grech, A, Van Os, J, Jones, PB, Lewis, SW, Murray, RM (2005). Cannabis use and outcome of recent onset psychosis. European Psychiatry 20, 349353.CrossRefGoogle ScholarPubMed
Henquet, C, Krabbendam, L, de Graaf, R, ten Have, M, van Os, J (2006). Cannabis use and expression of mania in the general population. Journal of Affective Disorders 95, 103110.CrossRefGoogle ScholarPubMed
Ihaka, R, Gentleman, R (1996). R: a language for data analysis and graphics. Journal of Computational and Graphical Statistics 5, 299314.Google Scholar
Kay, SR, Fiszbein, A, Opler, LA (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261276.CrossRefGoogle ScholarPubMed
Krishnadas, R, Jauhar, S, Telfer, S, Shivashankar, S, McCreadie, RG (2012). Nicotine dependence and illness severity in schizophrenia. British Journal of Psychiatry 201, 306312.CrossRefGoogle ScholarPubMed
Kuepper, R, van Os, J, Lieb, R, Wittchen, HU, Höfler, M, Henquet, C (2011). Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. British Medical Journal 342, d738.CrossRefGoogle ScholarPubMed
Large, M, Sharma, S, Compton, MT, Slade, T, Nielssen, O (2011). Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Archives of General Psychiatry 68, 555561.CrossRefGoogle ScholarPubMed
Manrique-Garcia, E, Zammit, S, Dalman, C, Hemmingsson, T, Andreasson, S, Allebeck, P (2012). Cannabis, schizophrenia and other non-affective psychoses: 35 years of follow-up of a population-based cohort. Psychological Medicine 42, 13211328.CrossRefGoogle ScholarPubMed
Mullin, K, Gupta, P, Compton, MT, Nielssen, O, Harris, A, Large, M (2012). Does giving up substance use work for patients with psychosis? A systematic meta-analysis. Australian and New Zealand Journal of Psychiatry 46, 826839.CrossRefGoogle ScholarPubMed
Murray, RM, Morrison, PD, Henquet, C, Di Forti, M (2007). Cannabis, the mind and society: the hash realities. Nature Reviews Neuroscience 8, 885895.CrossRefGoogle Scholar
Strakowski, SM, DelBello, MP, Fleck, DE, Adler, CM, Anthenelli, RM, Keck, PE Jr, Arnold, LM, Amicone, J (2007). Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania. Archives of General Psychiatry 64, 5764.CrossRefGoogle ScholarPubMed
van Dijk, D, Koeter, MW, Hijman, R, Kahn, RS, van den Brink, W (2012). Effect of cannabis use on the course of schizophrenia in male patients: a prospective cohort study. Schizophrenia Research 137, 5057.CrossRefGoogle ScholarPubMed
van Rossum, I, Boomsma, M, Tenback, D, Reed, C, van Os, J; EMBLEM Advisory Board (2009). Does cannabis use affect treatment outcome in bipolar disorder? A longitudinal analysis. Journal of Nervous and Mental Disease 197, 3540.CrossRefGoogle ScholarPubMed
Young, RC, Biggs, JT, Ziegler, VE, Meyer, DA (1978). A rating scale for mania: reliability, validity and sensitivity. British Journal of Psychiatry 133, 429435.CrossRefGoogle ScholarPubMed
Zammit, S, Moore, TH, Lingford-Hughes, A, Barnes, TR, Jones, PB, Burke, M, Lewis, G (2008). Effects of cannabis use on outcomes of psychotic disorders: systematic review. British Journal of Psychiatry 193, 357363.CrossRefGoogle ScholarPubMed
Zhang, XY, Chen, DC, Xiu, MH, Haile, CN, He, SC, Luo, X, Zuo, L, Rosenheck, R, Kosten, TA, Kosten, TR (2012). Cigarette smoking, psychopathology and cognitive function in first-episode drug-naive patients with schizophrenia: a case–control study. Psychological Medicine. Published online 13 11 2012 . doi:10.1017/S0033291712002590.Google ScholarPubMed